The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 04, 2022

Filed:

Oct. 28, 2020
Applicant:

Bioniz, Llc, Irvine, CA (US);

Inventors:

Nazli Azimi, San Juan Capistrano, CA (US);

Yutaka Tagaya, Rockville, MD (US);

Assignee:

BIONIZ, LLC, Irvine, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/10 (2006.01); A61K 38/20 (2006.01); A61K 8/64 (2006.01); A61K 47/64 (2017.01); A61Q 19/00 (2006.01); A61Q 19/08 (2006.01); A61Q 3/00 (2006.01); A61Q 7/00 (2006.01); C07K 14/52 (2006.01); C07K 14/54 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/55 (2006.01); A61P 17/18 (2006.01); A61P 31/14 (2006.01); A61P 35/00 (2006.01); G16B 15/00 (2019.01); G16B 20/00 (2019.01); G16B 35/00 (2019.01); G16C 20/60 (2019.01); G16B 35/20 (2019.01); G16B 20/50 (2019.01); G16B 20/30 (2019.01); G01N 33/50 (2006.01); G16B 15/30 (2019.01);
U.S. Cl.
CPC ...
G16B 15/00 (2019.02); G01N 33/5041 (2013.01); G16B 20/00 (2019.02); G16B 20/30 (2019.02); G16B 20/50 (2019.02); G16B 35/00 (2019.02); G16B 35/20 (2019.02); G16C 20/60 (2019.02); G01N 2333/54 (2013.01); G01N 2333/5412 (2013.01); G01N 2333/5443 (2013.01); G01N 2333/7155 (2013.01); G16B 15/30 (2019.02);
Abstract

Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.


Find Patent Forward Citations

Azimi, Nazli. (2022). Selective peptide antagonists (U.S. Patent No. 11462297). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11462297

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…